Alexion's Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms

Ultomiris, the successor to Alexion Pharmaceuticals Inc's ALXN paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster year.

• The drug posted $701 million in sales during 1H of 2021, Alexion said in a recent securities filing, a whopping 48% increase over the same period in 2020.
• After debuting with approval in adult PNH in late 2018, Ultomiris joined the blockbuster club in 2020 with $1.08 billion in sales.
• The older Soliris continued to deliver and posted first-half sales of $2.1 billion, a 5% Y/Y increase. 
• Overall revenues turned out to about $3.33 billion for the first half, a 15% increase over the $2.89 billion a year ago.
• Recently, Alexion announced topline results from Ultomiris Phase 3 study evaluating Ultomiris in generalized myasthenia. 
• Price Action: ALXN shares are up 1.34 at $181.85 during the market session on the last check Tuesday.